-
Treating Cancer Patients With COVID-19: A New York City ExperienceAn analysis of cancer patients who were infected with the coronavirus and treated at Memorial Sloan Kettering Cancer Center in New York City suggests certain risk factors may predict more severe COVID-19.
by Anna Azvolinsky
-
Exploring Immunotherapy for Triple Negative Breast CancerFollowing the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
Navigating Hospital Discharge DecisionsPatients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.
by Ashley P. Taylor
-
Immunotherapy in the ElderlyImmune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.
by Emma Yasinski
-
The Crowded Field of Checkpoint InhibitorsDrug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
by Kate Yandell
-
What Is Hyper-Progression?Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.
by Kate Yandell
-
First Immunotherapy Approved for Breast CancerMedical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.
by Anna Azvolinsky
-
An Uncommon PartnershipThrough the Angiosarcoma Project, researchers are partnering with patients to learn about a rare cancer.
by Ashley P. Taylor
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
A New Type of Drug ApprovalAt the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
Multiple myeloma survivor Jonathan Gluck reflects on uncertainty, and the scientific progress that has kept him living with cancer for more than two decades.
by Eric Fitzsimmons
The Enduring Importance of Cancer Disparities ResearchOpening session from AACR conference highlights how perseverance and adversity have informed cancer disparities research over the years.
by Eric Fitzsimmons
Most Cancer Survivors Don’t Meet Healthy Diet GoalsDespite research linking fruits and vegetables to cancer survival, many people do not change their eating habits after diagnosis.
by Darlene Dobkowski
Many People Don’t Get Colonoscopy After Receiving Abnormal Blood TestsAbout half of people who receive abnormal results from colorectal cancer screening tests don’t follow up with a colonoscopy.
by Laura Gesualdi Gilmore
-
Keeping Hope Alive—Why the Schlueters Rally for Medical ResearchRichard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed his treatment.
-
Cancer in the Rearview Mirror: 15 Years of AACR Cancer Progress Report Survivor StoriesCancer survivors profiled over the past 15 years in the AACR Cancer Progress Reports shared updates on their lives and the progress made against cancer.
Cancer Research at a Crossroads
